T cell co-regulatory signals and their role in cancer therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

T cell activation is initiated by signaling through the TCR after binding to MHC-presented antigen. Both positive and negative co-regulatory signaling can modify this original activating signal. T cell co-regulation is provided by receptors on the T cell surface membrane. Inhibitory signals are provided by CTLA4 or PD-1, while co-stimulation is provided by CD28, 4-1BB, OX40, or GITR. These signals are being studied in the laboratory and at the clinical level in order to therapeutically modulate T cell responses to tumor cells. T cells can recognize tumor antigens in the same way that these immune cells recognize bacteria, viral antigens, and other foreign peptides. If appropriately activated by the tumor antigen, the immune system can mediate an antitumor gene response. Unfortunately, immune cells with antitumor specifi city are not present in abundance and are often inhibited by tumor expression of CTLA4 or PD-1 ligands. Thus manipulation of co-regulatory signals can be used as a strategy by which to strengthen the immune response, via augmentation of T cell co-stimulation and/or blockade of inhibitory signals, in order to effectively treat cancer. In this chapter we review the basic principles and science as well as the ongoing clinical efforts in this area that have had recent success and offer additional promise.

Original languageEnglish (US)
Title of host publicationAdvances in Tumor Immunology and Immunotherapy
PublisherSpringer New York
Pages323-341
Number of pages19
ISBN (Electronic)9781461488095
ISBN (Print)9781461488088
DOIs
StatePublished - Jan 1 2014

Fingerprint

Regulatory T-Lymphocytes
T-Lymphocytes
Neoplasm Antigens
Neoplasms
Therapeutics
Viral Antigens
Immune System
Cell Membrane
Ligands
Bacteria
Antigens
Peptides
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Friedman, E. R., Feun, L. G., Benedetto, P. W., & Rosenblatt, J. D. (2014). T cell co-regulatory signals and their role in cancer therapy. In Advances in Tumor Immunology and Immunotherapy (pp. 323-341). Springer New York. https://doi.org/10.1007/978-1-4614-8809-5_14

T cell co-regulatory signals and their role in cancer therapy. / Friedman, Eitan R.; Feun, Lynn G; Benedetto, Pasquale W; Rosenblatt, Joseph D.

Advances in Tumor Immunology and Immunotherapy. Springer New York, 2014. p. 323-341.

Research output: Chapter in Book/Report/Conference proceedingChapter

Friedman, ER, Feun, LG, Benedetto, PW & Rosenblatt, JD 2014, T cell co-regulatory signals and their role in cancer therapy. in Advances in Tumor Immunology and Immunotherapy. Springer New York, pp. 323-341. https://doi.org/10.1007/978-1-4614-8809-5_14
Friedman ER, Feun LG, Benedetto PW, Rosenblatt JD. T cell co-regulatory signals and their role in cancer therapy. In Advances in Tumor Immunology and Immunotherapy. Springer New York. 2014. p. 323-341 https://doi.org/10.1007/978-1-4614-8809-5_14
Friedman, Eitan R. ; Feun, Lynn G ; Benedetto, Pasquale W ; Rosenblatt, Joseph D. / T cell co-regulatory signals and their role in cancer therapy. Advances in Tumor Immunology and Immunotherapy. Springer New York, 2014. pp. 323-341
@inbook{d14cbdcf253744cdbdcef3baeb632a1d,
title = "T cell co-regulatory signals and their role in cancer therapy",
abstract = "T cell activation is initiated by signaling through the TCR after binding to MHC-presented antigen. Both positive and negative co-regulatory signaling can modify this original activating signal. T cell co-regulation is provided by receptors on the T cell surface membrane. Inhibitory signals are provided by CTLA4 or PD-1, while co-stimulation is provided by CD28, 4-1BB, OX40, or GITR. These signals are being studied in the laboratory and at the clinical level in order to therapeutically modulate T cell responses to tumor cells. T cells can recognize tumor antigens in the same way that these immune cells recognize bacteria, viral antigens, and other foreign peptides. If appropriately activated by the tumor antigen, the immune system can mediate an antitumor gene response. Unfortunately, immune cells with antitumor specifi city are not present in abundance and are often inhibited by tumor expression of CTLA4 or PD-1 ligands. Thus manipulation of co-regulatory signals can be used as a strategy by which to strengthen the immune response, via augmentation of T cell co-stimulation and/or blockade of inhibitory signals, in order to effectively treat cancer. In this chapter we review the basic principles and science as well as the ongoing clinical efforts in this area that have had recent success and offer additional promise.",
author = "Friedman, {Eitan R.} and Feun, {Lynn G} and Benedetto, {Pasquale W} and Rosenblatt, {Joseph D}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-8809-5_14",
language = "English (US)",
isbn = "9781461488088",
pages = "323--341",
booktitle = "Advances in Tumor Immunology and Immunotherapy",
publisher = "Springer New York",

}

TY - CHAP

T1 - T cell co-regulatory signals and their role in cancer therapy

AU - Friedman, Eitan R.

AU - Feun, Lynn G

AU - Benedetto, Pasquale W

AU - Rosenblatt, Joseph D

PY - 2014/1/1

Y1 - 2014/1/1

N2 - T cell activation is initiated by signaling through the TCR after binding to MHC-presented antigen. Both positive and negative co-regulatory signaling can modify this original activating signal. T cell co-regulation is provided by receptors on the T cell surface membrane. Inhibitory signals are provided by CTLA4 or PD-1, while co-stimulation is provided by CD28, 4-1BB, OX40, or GITR. These signals are being studied in the laboratory and at the clinical level in order to therapeutically modulate T cell responses to tumor cells. T cells can recognize tumor antigens in the same way that these immune cells recognize bacteria, viral antigens, and other foreign peptides. If appropriately activated by the tumor antigen, the immune system can mediate an antitumor gene response. Unfortunately, immune cells with antitumor specifi city are not present in abundance and are often inhibited by tumor expression of CTLA4 or PD-1 ligands. Thus manipulation of co-regulatory signals can be used as a strategy by which to strengthen the immune response, via augmentation of T cell co-stimulation and/or blockade of inhibitory signals, in order to effectively treat cancer. In this chapter we review the basic principles and science as well as the ongoing clinical efforts in this area that have had recent success and offer additional promise.

AB - T cell activation is initiated by signaling through the TCR after binding to MHC-presented antigen. Both positive and negative co-regulatory signaling can modify this original activating signal. T cell co-regulation is provided by receptors on the T cell surface membrane. Inhibitory signals are provided by CTLA4 or PD-1, while co-stimulation is provided by CD28, 4-1BB, OX40, or GITR. These signals are being studied in the laboratory and at the clinical level in order to therapeutically modulate T cell responses to tumor cells. T cells can recognize tumor antigens in the same way that these immune cells recognize bacteria, viral antigens, and other foreign peptides. If appropriately activated by the tumor antigen, the immune system can mediate an antitumor gene response. Unfortunately, immune cells with antitumor specifi city are not present in abundance and are often inhibited by tumor expression of CTLA4 or PD-1 ligands. Thus manipulation of co-regulatory signals can be used as a strategy by which to strengthen the immune response, via augmentation of T cell co-stimulation and/or blockade of inhibitory signals, in order to effectively treat cancer. In this chapter we review the basic principles and science as well as the ongoing clinical efforts in this area that have had recent success and offer additional promise.

UR - http://www.scopus.com/inward/record.url?scp=85028500285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028500285&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-8809-5_14

DO - 10.1007/978-1-4614-8809-5_14

M3 - Chapter

SN - 9781461488088

SP - 323

EP - 341

BT - Advances in Tumor Immunology and Immunotherapy

PB - Springer New York

ER -